Chugai Pharmaceutical Co., Ltd. (CHGCY)
Data as of September 4, 2026 · Drug Manufacturers - General
Stockbruh grade: Strong 4/5 metrics rated Sunny
What does Chugai Pharmaceutical Co., Ltd. do?
Chugai Pharmaceutical Co., Ltd. rocks the pharma game with a killer lineup of oncology, osteoporosis, renal diseases, and more. Based in Tokyo, Japan, this company collaborates with the Roche Group and brings the heat with products like Avastin and Hemlibra. They're all about saving lives and making a difference! 💊🔥 #PharmaPowerhouse.
Key Numbers
| Metric | Rating | What it means |
|---|
| Returns (5Y) | ⛅ Moderate | 5-year price performance |
| Profitability | ☀️ Strong | Net margin & return on equity |
| Growth | ☀️ Strong | Revenue & earnings trend |
| Earnings | ☀️ Strong | EPS vs analyst expectations |
| Cash & Debt | ☀️ Strong | Balance sheet strength |
| Price | $21.99 | Market Cap | — |
| Exchange | Other OTC | | |
Plain-English Analysis
What's it worth?
Performance has been moderate. Sign up free to see Stockbruh's full valuation analysis including price ratios and plain-English commentary.
Are they building the future?
Revenue and earnings are trending upward — Chugai Pharmaceutical Co., Ltd. appears to be growing. Sign up free for the full growth analysis including year-over-year comparisons and R&D investment data.
What's ahead?
Recent earnings have been strong, meeting or beating analyst expectations. Sign up free for earnings history, EPS trends, and what analysts are forecasting next.